Recall Of Valiant Navion Could Cost Medtronic $40M
Executive Summary
The company ordered the recall after three stent fractures and a death occurred in an 89-participant clinical trial.
You may also be interested in...
It’s Class I For Medtronic’s Valiant Navion Recall
The US FDA gave its highest risk classification to a recent recall of the Valiant Navion Thoracic Stent Graft System. Two serious injuries and one death – a clinical trial participant – were reported.
Recall Of Medtronic’s HeartWare Pump Kits Labeled Class I By FDA; Deaths, Injuries Reported
The recall of the kit, which is part of the HeartWare HVAD System, was affixed with the US agency’s highest risk classification on 1 March.
Results Recap: Medtronic's Valiant Navion Earns FDA Approval Based On 30-Day Results
Results Recap is Medtech Insight's exclusive summary of clinical trial results that have been announced or published in the past week, based on information collected by Meddevicetracker. This week's edition covers the week of Oct. 19 - Oct. 25, including trial announcements from Medtronic, iCAD, PharmaEngine, Inc., Nanobiotix SA, and Myriad Genetics.